Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.605, 2010-01, pp. : 13-13
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Nilotinib, dasatinib or imatinib in CML: no clear winner
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :
Access to resources
Recommend
Nilotinib better than imatinib, dasatinib for CML in Colombia
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 645, 2012-01 ,pp. :
Nilotinib launched for Ph+ CML in the UK.
Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. :
Dasatinib/imatinib/nilotinib: Cardiomyopathy (first report for nilotinib): case report
Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. :
Evidence for dasatinib, nilotinib "too poor" − NICE
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 598, 2010-01 ,pp. :